ClearPoint Neuro, Inc. (CLPT)
| Market Cap | 278.81M -59.6% |
| Revenue (ttm) | 42.28M +25.9% |
| Net Income | -34.57M |
| EPS | -1.18 |
| Shares Out | 30.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 355,472 |
| Open | 9.19 |
| Previous Close | 9.25 |
| Day's Range | 8.95 - 9.22 |
| 52-Week Range | 8.27 - 27.27 |
| Beta | 1.29 |
| Analysts | Strong Buy |
| Price Target | 23.50 (+157.11%) |
| Earnings Date | Oct 28, 2026 |
About CLPT
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint softwa... [Read more]
Financial Performance
In 2025, ClearPoint Neuro's revenue was $36.97 million, an increase of 17.78% compared to the previous year's $31.39 million. Losses were -$25.54 million, 35.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for CLPT stock is "Strong Buy." The 12-month stock price target is $23.5, which is an increase of 157.11% from the latest price.
News
ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026
SOLANA BEACH, CA / ACCESS Newswire / October 14, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to th...
CLPT Investors with $100,000 in Losses Have Opportunity to Join ClearPoint Neuro, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $CLPT--CLPT Investors with $100,000 in Losses Have Opportunity to Join ClearPoint Neuro, Inc. Fraud Investigation with SBS Law.
ClearPoint Neuro price target lowered to $25 from $30 at Lake Street
Lake Street lowered the firm’s price target on ClearPoint Neuro (CLPT) to $25 from $30 and keeps a Buy rating on the shares. Management’s deliberate decision to invest in its…
ClearPoint Neuro price target lowered to $22 from $25 at Stifel
Stifel analyst Tom Stephan lowered the firm’s price target on ClearPoint Neuro (CLPT) to $22 from $25 and keeps a Buy rating on the shares.
ClearPoint Neuro cuts FY26 revenue view to $48M-$52M from $52M-$56M
Consensus $53.13M. The company said, “As we embrace this new and important market information, our revised 2026 priorities are designed to build capacity across the full development pathway, from prec...
ClearPoint Neuro reports Q2 EPS (38c), consensus (29c)
Reports Q2 revenue $10.88M, consensus $12.73M. “Establishing ClearPoint Neuro (CLPT) as the leading neuro cell and gene therapy delivery company has been our number one priority for the last 10…
ClearPoint Neuro Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 18% year-over-year to $10.9M, with strong gains in navigation and capital equipment segments, but a decline in biologics due to a non-recurring order. Strategic focus shifted to clinical support, CAL facility ramp, and technology development, with 2026 revenue guidance set at $48–$52M and high-teen to 20% growth expected for 2027.
ClearPoint Neuro Earnings release: Q2 2026
ClearPoint Neuro released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
ClearPoint Neuro Slides: Q2 2026
ClearPoint Neuro has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.
ClearPoint Neuro Quarterly report: Q2 2026
ClearPoint Neuro has published its Q2 2026 quarterly earnings report on August 3, 2026.
ClearPoint Neuro Reports Second Quarter 2026 Results
Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion SOLANA BEACH, CA / ACCESS Newswire / August 3, 2026 / ClearPoint Neuro, Inc. (Nasda...
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel
RMAT Designation Supports an Expedited FDA Development and Review Pathway for Aspen's Investigational Autologous Cell Replacement Therapy for Parkinson's Disease. SOLANA BEACH, CA / ACCESS Newswire / ...
ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026
SOLANA BEACH, CA / ACCESS Newswire / July 21, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the b...
ClearPoint Neuro price target raised to $30 from $20 at B. Riley
B. Riley analyst Anderson Schock raised the firm’s price target on ClearPoint Neuro (CLPT) to $30 from $20 and keeps a Buy rating on the shares. ClearPoint Neuro is a…
ClearPoint Neuro up 32% after uniQure announces plan for AMT-130 BLA submission
Shares of ClearPoint Neuro (CLPT) are up $4.32, or 32%, to $17.66 in pre-market trading after partner uniQure (QURE) announced during a recent Type B meeting with the FDA that…
ClearPoint Neuro enters development partnership with Sungkyunkwan University
ClearPoint Neuro (CLPT) announced plans to enter the focused ultrasound market and demonstrated successful intravenous delivery of tracers across the blood-brain barrier in a preclinical model using a...
ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
Announcement is made after successful proof-of-concept trial in a preclinical model of intravenous delivery of large molecule tracers across the blood-brain barrier guided by prototype systems, includ...
ClearPoint Neuro receives CE Marking for Velocity Alpha MR
ClearPoint Neuro (CLPT) announced that the Velocity Alpha MR High Speed Surgical Drill System has received CE Marking in addition to the existing FDA 510(k) clearance in the United States.
ClearPoint Neuro reports Q1 EPS (32c) vs. (22c) last year
Reports Q1 revenue $12.1M vs. $8.5M last year. Neurosurgery navigation, therapy and access revenue increased 80% to $5.9M, driven by additional revenues from sales of the IRRAflow product and the…
ClearPoint Neuro sees FY26 revenue $52M-$56M, consensus $53.03M
The company expects cost synergies resulting from the acquisition of IRRAS to contribute to a reduction in cash burn in the second half of 2026 and believes the asset integration…
ClearPoint Neuro Earnings Call Transcript: Q1 2026
Record Q1 2026 revenue of $12.1M (43% growth) driven by organic and IRRAflow contributions, with gross margin up to 64%. 2026 revenue is guided at $52–$56M, all segments expected to grow double digits, and integration synergies are improving margins and global reach.
ClearPoint Neuro Earnings release: Q1 2026
ClearPoint Neuro released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
ClearPoint Neuro Quarterly report: Q1 2026
ClearPoint Neuro has published its Q1 2026 quarterly earnings report on May 13, 2026.
ClearPoint Neuro Reports First Quarter 2026 Results
Record Revenue Achieved Including 25% Organic Growth in Devices and 43% Overall Growth SOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a globa...
ClearPoint Neuro Announces CE Marking of Velocity Alpha MR High Speed Surgical Drill System, Further Expanding Drug Delivery Ecosystem and Global Footprint
SOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain ...